Zhengye Biotechnology Holding Ltd Dossier
|
SectorHealth Care IndustrySpecialty & Generic Pharmaceuticals Beta (adjusted)0.63 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.20Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $56.9M Enterprise Value $81.2M Shares Outstanding 47.4M diluted Moat Rating None Next Earnings Date30 Apr 2027 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Zhengye Biotechnology Holding Limited (ZYBT) is facing severe operational and regulatory headwinds. The company's financial performance deteriorated significantly in fiscal year 2025, with revenues declining by 37.6% to RMB116.4 million and gross margins compressing from 49.0% to 20.5%, resulting in a net loss of RMB83.0 million. This downturn was primarily driven by a cyclical decline in the Chinese hog market and government macro-control policies that reduced swine vaccine demand. Compounding these operational challenges are critical listing compliance risks, including a Nasdaq minimum bid price deficiency notice received in June 2026 and board independence non-compliance following director resignations. Given the high volatility, micro-cap status, and lack of near-term catalysts to reverse swine market dynamics, a cautious stance is warranted. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $0.3020% Swine market weakness persists longer than expected, and R&D investments fail to yield high-margin commercial products. The company fails to regain compliance with Nasdaq's minimum bid price rule or board independence requirements, leading to delisting from the Nasdaq Capital Market to the OTC markets, severely impacting liquidity and valuation. Base CaseCentral scenario $0.8060% The Chinese swine market remains consolidated and slow to recover, keeping swine vaccine revenues under pressure. The company relies on its smaller poultry and sheep vaccine segments to stabilize the top line while continuing to invest in R&D. ZYBT likely executes a reverse stock split to cure its Nasdaq minimum bid price deficiency, which prevents delisting but remains dilutive or neutral to equity value. Bull CaseUpside scenario $1.5020% A rapid cyclical recovery in the Chinese hog market drives a surge in swine vaccine demand. Concurrently, the company successfully commercializes its newly approved National Category I and Category III veterinary drugs, while expanding its international footprint in Egypt, Pakistan, and Vietnam. The company regains Nasdaq compliance without dilutive measures, restoring investor confidence. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |